Trial Profile
An open-label, parallel study of evolocumab in subjects with or without hepatic impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 09 Nov 2016 New trial record
- 26 Sep 2016 Results published in the Journal of Clinical Pharmacology.